Story perspectives

Regeneron Secures $10B MFN Deal, Medicaid Cuts, Gene Therapy Approval

4/24/2026

Summary

Story summary

Regeneron became the pharma to sign a most-favored-nation pricing pact with the Trump administration, pledging $10 billion in production.
President Donald Trump announced Medicaid price cuts for Regeneron drugs and a $225 Praluent on TrumpRx.
The firm won FDA approval for Otarmeni gene therapy, which will be free for eligible children with rare hearing loss.
Health Secretary Robert F. Kennedy Jr. said details will be shared and urged Congress to codify pricing.

1 of 1

Story summary

Regeneron became the pharma to sign a most-favored-nation pricing pact with the Trump administration, pledging $10 billion in production.
President Donald Trump announced Medicaid price cuts for Regeneron drugs and a $225 Praluent on TrumpRx.
The firm won FDA approval for Otarmeni gene therapy, which will be free for eligible children with rare hearing loss.
Health Secretary Robert F. Kennedy Jr. said details will be shared and urged Congress to codify pricing.